Dexcom Unlocks Access to Real-Time CGM for a Further Half a Million People With Diabetes in France
September 12 2023 - 3:00AM
Business Wire
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time
continuous glucose monitoring for people with diabetes, today
announced the availability of its Dexcom ONE real-time CGM sensor
via reimbursement, in France.
Dexcom’s announcement brings the company’s highly researched and
studied, real-time CGM technology to half a million more people
with diabetes in France. Specifically, access is now secured to the
Dexcom ONE sensor for all patients with type 1 and type 2 diabetes,
two years and older, who are undergoing intensive insulin therapy
(by external pump or >3 injections per day).
The proven accuracy of Dexcom ONE1# allows people to make
confident treatment decisions in real-time, without scanning, and
as a real-time CGM with alerts, is shown to improve time-in-range
significantly more than Flash Glucose Monitoring (isCGM)2§.
“We believe this is truly exciting news for people living with
diabetes in France,” said Gérald Zammit, Country Director of Dexcom
France. "Access to Dexcom real-time CGM sensors is now available to
those who live with diabetes, who aren’t necessarily seen as ‘high
risk’, but who can still greatly benefit from it. The launch of
Dexcom ONE in France will help to make real-time CGM accessible to
as many patients as possible.”
Dexcom real-time CGM use is clinically proven to lower HbA1C,
reduce hyper- and hypoglycaemia, and increase time in range3-5.
The launch of Dexcom ONE in France means patients now have
access to a choice of Dexcom real-time CGM sensors, the Dexcom G6
continues to offer Type 1, high risk, patients industry-leading
connectivity through integrations with leading insulin delivery
systems and digital health apps.
§ Results obtained with an rt-CGM with alerts, similar to Dexcom
ONE, and compared to Freestyle Libre 1. # Results obtained with
Dexcom G6, which uses the same applicator and sensor (and
algorithm) as Dexcom ONE 1 Shah VN, et al. Diabetes Technol Ther.
2018;20(6):428-433. 2 Haskova et al. Diabetes Care.
2020;43(11):2744-2750. 3 Beck, RW, et al. JAMA.
2017;317(4):371-378. 4 Welsh, JB et al. Diabetes Technol Ther.
2019;21(3):128-132. 5. Beck RW, et al. Ann Intern Med.
2017;167(6):365-374.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230911959810/en/
Gemma McDonald EMEA PR Manager gemma.mcdonald@dexcom.com
James McIntosh Global PR Director james.mcintosh@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jun 2024 to Jul 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Jul 2023 to Jul 2024